FDA Ends Regularly Scheduled Patient-Focused Drug Development Meetings
Executive Summary
After conducting 24 disease-focused meetings in five years, FDA moving to next phase of patient interaction under new user fee cycle.
You may also be interested in...
FDA Considers Incorporating Patient Input In Generic Drug Assessments
The popular patient-focused drug development model for new drugs might not fit for generics, in part because the affected patient groups would be much larger.
US FDA Considers Incorporating Patient Input In Generic Drug Assessments
But the popular patient-focused drug development model for new drugs might not fit for generics, in part because the affected patient groups would be much larger.
US FDA Expands Patient Input To New Area: Orphan Grant Applications
Patient experience will be incorporated into agency orphan grant reviews, and outside rare disease experts will help make decisions.